KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Aquestive Therapeutics (AQST) EBIT Margin: 2017-2024

Historic EBIT Margin for Aquestive Therapeutics (AQST) over the last 8 years, with Dec 2024 value amounting to -3,052.68%.

  • Aquestive Therapeutics' EBIT Margin fell 2841.00% to -89.63% in Q3 2025 from the same period last year, while for Sep 2025 it was 424.07%, marking a year-over-year increase of 45990.00%. This contributed to the annual value of -3,052.68% for FY2024, which is 302282.00% down from last year.
  • Aquestive Therapeutics' EBIT Margin amounted to -3,052.68% in FY2024, which was down 10,124.71% from -29.86% recorded in FY2023.
  • Aquestive Therapeutics' 5-year EBIT Margin high stood at -29.86% for FY2023, and its period low was -3,052.68% during FY2024.
  • Its 3-year average for EBIT Margin is -1,056.92%, with a median of -88.23% in 2022.
  • Its EBIT Margin has fluctuated over the past 5 years, first spiked by 100,410bps in 2021, then crashed by 302,282bps in 2024.
  • Yearly analysis of 5 years shows Aquestive Therapeutics' EBIT Margin stood at -1,072.33% in 2020, then skyrocketed by 100,410bps to -68.22% in 2021, then tumbled by 2,000bps to -88.23% in 2022, then skyrocketed by 5,837bps to -29.86% in 2023, then slumped by 302,282bps to -3,052.68% in 2024.